DUSA Pharmaceuticals Inc. has announced the completion for the enrollment of acne Phase IIb trial. The company plans to study the effects of multiple broad area photodynamic therapy (PDT) treatments, Levulan®, Kerastick® and BLU-U® brands as compared to the use of BLU-U® alone. Thus, the company will be able to evaluate the incremental advantage of Levulan® along with BLU-U® blue light therapy in acne treatment.